Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
3 Biotech Stocks With a Cash Pile Higher Than Their Valuations
12:00pm, Saturday, 21'st May 2022 The Motley Fool
Our roundtable found three biotechs with a nice cash cushion.
Top Research Reports for JPMorgan, Gilead Sciences & CSX
05:08pm, Friday, 20'th May 2022 Zacks Investment Research
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Gilead Sciences, Inc. (GILD) and CSX Corporation (CSX).
Recent Stock Purchase May 2022
05:41pm, Thursday, 19'th May 2022
I have added to my taxable account 3.6133 shares for a total investment of $250.00 in Starbucks Corporation. I have added to my taxable account 11.5718 shares for a total investment of $550.00 in Ve
Biotech Stock Roundup: BBIO Up on BMY Deal, GILD & CMRX Offer Updates
03:41pm, Wednesday, 18'th May 2022 Zacks Investment Research
Regulatory updates and acquisition news from Bristol Myers' (BMY) and BridgeBio Pharma (BBIO) are a few key highlights from the biotech sector during the past week.
Gilead (GILD) HIV Studies Removed From FDA's Clinical Hold
03:30pm, Tuesday, 17'th May 2022 Zacks Investment Research
Gilead (GILD) studies evaluating injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP) removed from hold.
Gilead (GILD) HIV Studies Removed From FDA's Clinical Hold
12:47pm, Tuesday, 17'th May 2022
Gilead (GILD) studies evaluating injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP) removed from hold.
Should You Invest in the VanEck Biotech ETF (BBH)?
10:20am, Monday, 16'th May 2022 Zacks Investment Research
Sector ETF report for BBH
Roche (RHHBY) Phase III NSCLC Study Disappoints, Stock Down
01:57pm, Thursday, 12'th May 2022 Zacks Investment Research
Roche (RHHBY) stock declines as the late-stage study evaluating tiragolumab plus Tecentriq fails to meet its co-primary endpoint of progression-free survival.
2 Red Flags for Gilead Sciences' Future
03:45pm, Wednesday, 11'th May 2022 The Motley Fool
Consider these issues before buying shares of the drugmaker.
How Are Biotech ETFs Reacting to These Q1 Earnings Releases?
06:05pm, Tuesday, 10'th May 2022 Zacks Investment Research
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
How Are Biotech ETFs Reacting to These Q1 Earnings Releases?
03:48pm, Tuesday, 10'th May 2022
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
10:20am, Tuesday, 10'th May 2022 Zacks Investment Research
Smart Beta ETF report for IBB
Mizuho: these two biotech stocks are worth buying right now
08:35pm, Monday, 09'th May 2022 Invezz
Biotech is one of the hardest hit sectors this year, with the SPDR S&P Biotech ETF now down 45% year-to-date. Still, a Mizuho analyst says the following two stocks are worth buying. Syed sees signific
RBC Expects Business Development To Unlock This Pharma Stock's Balance Sheet Value
07:30pm, Monday, 09'th May 2022 Benzinga
RBC Capital Markets views Galapagos' NV (NASDAQ: GLPG) Q1 Jyseleca revenues in line as the story focuses on whether new leadership can unlock value from GLPG's ample balance sheet.
Jyseleca's Q1 s
Mizuho: these two biotech stocks are worth buying right now
04:35pm, Monday, 09'th May 2022
Biotech is one of the hardest hit sectors this year, with the SPDR S&P Biotech ETF now down 45% year-to-date. Still, a Mizuho analyst says the following two stocks are worth buying.
